The market for CombiGene’s epilepsy project
Epilepsy is a global problem. The disease affects an estimated 0.6 to 0.8 percent of the world’s population. In 2016 there were 5.7 million diagnosed epilepsy patients in the USA, the EU5* and Japan. About one-third of these patients do not respond to conventional medical treatment. It is this patient group CombiGene intends to help with its candidate drug, CG01.
* EU5 = France, Germany, Italy, Spain and United Kingdom
Enormous potential for CombiGene
In the USA alone some 14,000 patients are diagnosed with drug-resistant focal epilepsy each year, patients who could be candidates for surgery. CombiGene estimates that, realistically, 10–20 percent of these patients could be treated with the company’s candidate drug, CG01. Assuming that the treatment cost per patient could amount to USD 200,000, sales could be as much as between EUR 280 to 560 million. Globally, the corresponding figure is between EUR 0.9 to 1.8 billion.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.